# Clinical Trials Data ALK - Document 31

# The Oncopanel Pilot (TOP) Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02171286

"eligibilityCriteria": "Patients with archival tumor tissue and a known history of invasive malignancies are eligible if they meet one or more of the following criteria:\n\n\* Advanced colorectal cancer and eligible for standard KRAS testing,\n\* Advanced non-small cell lung cancer and eligible for standard EGFR testing,\n\* Advanced melanoma and eligible for standard BRAF testing,\n\* Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing,\n\* Being considered for potential eligibility in clinical trial.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced colorectal cancer, non-small cell lung cancer and melanoma and candidates for clinical trials.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not explicitly include\*\* patients with ALK gene mutations. The eligibility criteria lists specific cancer types and associated standard genetic tests (KRAS for colorectal, EGFR for lung, BRAF for melanoma, c-KIT and PDGFRA for GIST). ALK testing is not mentioned.  
  
While the last bullet point mentions consideration for other trials, this is vague and doesn't guarantee eligibility based on an ALK mutation. It's possible that having an ALK mutation \*might\* open the door to a separate trial being considered, but this trial's description doesn't explicitly cover it. Therefore, based on this information alone, a patient with \*only\* an ALK mutation wouldn't automatically qualify. They would need to meet one of the other listed criteria or have the ALK mutation be relevant to another trial being considered through this study's somewhat ambiguous final criterion.